Cardiovascular Safety of Romosozumab: New Insights from Postmenopausal Women with Chronic Kidney Disease

J Bone Miner Res. 2023 Feb;38(2):354-355. doi: 10.1002/jbmr.4724. Epub 2022 Nov 4.

Authors

Giovanni Adami¹, Davide Gatti¹, Angelo Fassio¹, Ombretta Viapiana¹, Maurizio Rossini¹

Affiliation

¹ Rheumatology Unit, University of Verona, Verona, Italy.

PMID: 36330828
DOI: 10.1002/jbmr.4724

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / adverse effects
Bone Density
Bone Density Conservation Agents*
Denosumab
Female
Humans
Osteoporosis, Postmenopausal*
Postmenopause
Renal Insufficiency, Chronic* / drug therapy

Substances

romosozumab
Antibodies, Monoclonal
Denosumab
Bone Density Conservation Agents